157 related articles for article (PubMed ID: 35681744)
1. mTORC1-Inhibition Potentiating Metabolic Block by Tyrosine Kinase Inhibitor Ponatinib in Multiple Myeloma.
Nazim UM; Bishayee K; Kang J; Yoo D; Huh SO; Sadra A
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681744
[TBL] [Abstract][Full Text] [Related]
2. Reversing the HDAC-inhibitor mediated metabolic escape in MYCN-amplified neuroblastoma.
Bishayee K; Nazim UM; Kumar V; Kang J; Kim J; Huh SO; Sadra A
Biomed Pharmacother; 2022 Jun; 150():113032. PubMed ID: 35486977
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
4. mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells.
Pusapati RV; Daemen A; Wilson C; Sandoval W; Gao M; Haley B; Baudy AR; Hatzivassiliou G; Evangelista M; Settleman J
Cancer Cell; 2016 Apr; 29(4):548-562. PubMed ID: 27052953
[TBL] [Abstract][Full Text] [Related]
5. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity.
Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F
PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526
[TBL] [Abstract][Full Text] [Related]
6. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.
Shen YC; Ou DL; Hsu C; Lin KL; Chang CY; Lin CY; Liu SH; Cheng AL
Br J Cancer; 2013 Jan; 108(1):72-81. PubMed ID: 23257894
[TBL] [Abstract][Full Text] [Related]
7. Proliferating tumor cells mimick glucose metabolism of mature human erythrocytes.
Ghashghaeinia M; Köberle M; Mrowietz U; Bernhardt I
Cell Cycle; 2019 Jun; 18(12):1316-1334. PubMed ID: 31154896
[TBL] [Abstract][Full Text] [Related]
8. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
Du D; Liu C; Qin M; Zhang X; Xi T; Yuan S; Hao H; Xiong J
Acta Pharm Sin B; 2022 Feb; 12(2):558-580. PubMed ID: 35256934
[TBL] [Abstract][Full Text] [Related]
9. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTORC1 signaling sensitizes hepatocellular carcinoma cells to glycolytic stress.
Zhao X; Jiang P; Deng X; Li Z; Tian F; Guo F; Li X; Wang S
Am J Cancer Res; 2016; 6(10):2289-2298. PubMed ID: 27822418
[TBL] [Abstract][Full Text] [Related]
11. Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors.
Christians U; Gottschalk S; Miljus J; Hainz C; Benet LZ; Leibfritz D; Serkova N
Br J Pharmacol; 2004 Oct; 143(3):388-96. PubMed ID: 15339861
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines.
Mingard C; Paech F; Bouitbir J; Krähenbühl S
J Appl Toxicol; 2018 Mar; 38(3):418-431. PubMed ID: 29072336
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin Suppresses Tumor Growth and Alters the Metabolic Phenotype in T-Cell Lymphoma.
Kittipongdaja W; Wu X; Garner J; Liu X; Komas SM; Hwang ST; Schieke SM
J Invest Dermatol; 2015 Sep; 135(9):2301-2308. PubMed ID: 25897830
[TBL] [Abstract][Full Text] [Related]
14. mTOR-mediated metabolic reprogramming shapes distinct microglia functions in response to lipopolysaccharide and ATP.
Hu Y; Mai W; Chen L; Cao K; Zhang B; Zhang Z; Liu Y; Lou H; Duan S; Gao Z
Glia; 2020 May; 68(5):1031-1045. PubMed ID: 31793691
[TBL] [Abstract][Full Text] [Related]
15. Caffeic Acid Targets AMPK Signaling and Regulates Tricarboxylic Acid Cycle Anaplerosis while Metformin Downregulates HIF-1α-Induced Glycolytic Enzymes in Human Cervical Squamous Cell Carcinoma Lines.
Tyszka-Czochara M; Bukowska-Strakova K; Kocemba-Pilarczyk KA; Majka M
Nutrients; 2018 Jun; 10(7):. PubMed ID: 29958416
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of Tumor Cells and Tumor Immune Microenvironment Vulnerabilities.
Kalyanaraman B; Cheng G; Hardy M
Front Oncol; 2022; 12():816504. PubMed ID: 35756631
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
Xu RH; Pelicano H; Zhang H; Giles FJ; Keating MJ; Huang P
Leukemia; 2005 Dec; 19(12):2153-8. PubMed ID: 16193082
[TBL] [Abstract][Full Text] [Related]
18. An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1
Xu S; Zhou T; Doh HM; Trinh KR; Catapang A; Lee JT; Braas D; Bayley NA; Yamada RE; Vasuthasawat A; Sasine JP; Timmerman JM; Larson SM; Kim Y; MacLeod AR; Morrison SL; Herschman HR
Cancer Res; 2019 May; 79(10):2748-2760. PubMed ID: 30885978
[TBL] [Abstract][Full Text] [Related]
19. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.
DeWaal D; Nogueira V; Terry AR; Patra KC; Jeon SM; Guzman G; Au J; Long CP; Antoniewicz MR; Hay N
Nat Commun; 2018 Jan; 9(1):446. PubMed ID: 29386513
[TBL] [Abstract][Full Text] [Related]
20. Methylation-associated silencing of miR-9-1 promotes nasopharyngeal carcinoma progression and glycolysis via HK2.
Xu QL; Luo Z; Zhang B; Qin GJ; Zhang RY; Kong XY; Tang HY; Jiang W
Cancer Sci; 2021 Oct; 112(10):4127-4138. PubMed ID: 34382305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
